Unmasked Brugada pattern by ajmaline challenge in patients with myotonic dystrophy type 1

Annals of Noninvasive Electrocardiology

Volumn 20, Issue 1, 2015, Pages 28-36

  Pambrun, Thomas ^a,b   Bortone, Agustín ^b   Bois, Patrick ^c   Degand, Bruno ^a   Patri, Sylvie ^c   Mercier, Aurélie ^c   Chahine, Mohamed ^d   Chatelier, Aurélien ^c   Coisne, Damien ^a   Amiel, Alain ^a  

^a POITIERS UNIVERSITY HOSPITAL   (France)

^b Cardiology Department   (France)

^c UNIVERSITÉ DE POITIERS   (France)

^d CENTRE DE RECHERCHE DE L INSTITUT UNIVERSITAIRE EN SANTÉ MENTALE DE QUÉBEC   (Canada)

Author keywords

ajmaline challenge; Brugada syndrome; cardiac arrhythmia; myotonic dystrophy type 1; sodium channels

Indexed keywords

AJMALINE; ANTIARRHYTHMIC AGENT;

ADULT; AGED; ARTICLE; BRUGADA SYNDROME; CARDIAC RESYNCHRONIZATION THERAPY; CLINICAL ARTICLE; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEART ELECTROPHYSIOLOGY; HEART LEFT BUNDLE BRANCH BLOCK; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE TACHYCARDIA; HUMAN; HUMAN TISSUE; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MALE; MIDDLE AGED; MYOTONIC DYSTROPHY; PRIORITY JOURNAL; SUDDEN CARDIAC DEATH; TREATMENT RESPONSE; ADOLESCENT; COMPLICATION; ELECTROCARDIOGRAPHY; PATHOPHYSIOLOGY; PROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; AJMALINE; ANTI-ARRHYTHMIA AGENTS; BRUGADA SYNDROME; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYOTONIC DYSTROPHY; PROSPECTIVE STUDIES;

EID: 84920716898     PISSN: 1082720X     EISSN: 1542474X     Source Type: Journal    
DOI: 10.1111/anec.12168     Document Type: Article

References (23)

1. Brook JD, McCurrach ME, Harley HG, et al. Molecular basis of myotonic dystrophy: Expansion of a trinucleotide (CTG) repeat at the 3′ end of a transcript encoding a protein kinase family member. Cell 1992; 68: 799-808.
2. th European Neuromuscular Centre International Workshop: Myotonic dystrophy: Present management, future therapy. Neuromuscul Disord 2002; 12: 596-599.
3. Groh WJ, Groh MR, Saha C, et al. Electrocardiographic abnormalities and sudden death in myotonic dystrophy type 1. N Engl J Med 2008; 358: 2688-2697.
4. Wahbi K, Meune C, Porcher R, et al. Electrophysiological study with prophylactic pacing and survival in adults with myotonic dystrophy and conduction system disease. JAMA 2012; 307: 1292-1301.
5. Brignole M, Auricchio A, Baron-Esquivias G, et al. 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Europace 2013; 15: 1070-1118.
6. Kanadia RN, Johnston KA, Mankodi A, et al. A muscleblind knockout model for myotonic dystrophy. Science 2003; 302 (5652): 1978-1980.
7. Antzelevitch C, Brugada P, Borggrefe M, et al. Brugada syndrome: Report of the second consensus conference: Endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation 2005; 111: 659-670.
8. Wahbi K, Algalarrondo V, Becane HM, et al. Brugada syndrome and abnormal splicing of SCN5A in myotonic dystrophy type 1. Arch Cardiovasc Dis 2013; 106: 635-643.
9. Mathieu J, Boivin H, Meunier D, et al. Assessment of a disease specific muscular impairment rating scale in myotonic dystrophy. Neurology 2001; 56: 336-340.
10. Veltmann C, Papavassiliu T, Konrad T, et al. Insights into the location of type 1 ECG in patients with Brugada syndrome: Correlation of ECG and cardiovascular magnetic resonance imaging. Heart Rhythm 2012; 9: 414-421.
11. Govindan M, Batchvarov VN, Raju H, et al. Utility of high and standard right precordial leads during ajmaline testing for the diagnosis of Brugada syndrome. Heart 2010; 96: 1904-1908.
12. Wang Q, Li Z, Shen J, et al. Genomic organization of the human SCN5A gene encoding the cardiac sodium channel. Genomics 1996; 34: 9-16.
13. Conte G, Sieira J, Sarkozy A, et al. Life-threatening ventricular arrhythmias during ajmaline challenge in patients with Brugada syndrome: Incidence, clinical features, and prognosis. Heart Rhythm 2013; 10: 1869-1874.
14. Komajda M, Frank R, Vedel J, et al. Intracardiac conduction defects in dystrophia myotonica. Electrophysiological study of 12 cases. Br Heart J 1980; 43: 315-320.
15. Hermans MC, Faber CG, Bekkers SC, et al. Structural and functional cardiac changes in myotonic dystrophy type 1: A cardiovascular magnetic resonance study. J Cardiovasc Magn Reson 2012; 14: 48.
16. Vignaux O, Lazarus A, Varin J, et al. Right ventricular MR abnormalities in myotonic dystrophy and relationship with intracardiac electrophysiologic test findings: Initial results. Radiology 2002; 224 (1): 231-235.
17. Ohkubo K, Watanabe I, Okumura Y, et al. Right ventricular histological substrate and conduction delay in patients with Brugada syndrome. Int Heart J 2010; 51: 17-23.
18. Nademanee K, Veerakul G, Chandanamattha P, et al. Prevention of ventricular fibrillation episodes in Brugada syndrome by catheter ablation over the anterior right ventricular outflow tract epicardium. Circulation 2011; 123: 1270-1279.
19. Vetmann C, Wolpert C, Sacher F, et al. Response to intravenous ajmaline: A retrospective analysis of 677 ajmaline challenges. Europace 2009; 11: 1345-1352.
20. Otten RF, Scherschel JA, Lopshire JC, et al. Arrhythmia exacerbation after sodium channel blockade in myotonic dystrophy type 1. Muscle Nerve 2009; 40: 901-902.
21. Obayashi K, Mandel WJ,. Electrophysiological effects of ajmaline in isolated cardiac tissue. Cardiovasc Res 1976; 10: 20-24.
22. Gronda M, Magnani A, Occhetta E, et al. Electrophysiological study of atrio-ventricular block and ventricular conduction defects. Prognostic and therapeutical implications. G Ital Cardiol 1984; 14: 768-773.
23. Babuty D, Fauchier L, Tena-Carbi D, et al. Is it possible to identify infrahissian cardiac conduction abnormalities in myotonic dystrophy by non-invasive methods ? Heart 1999; 82: 634-637.